Skip to main content

Intraocular surgery under adalimumab therapy in patients with refractory uveitis: a single center study of 23 eyes

Abstract

Purpose

We assessed the efficacy and safety of performing intraocular surgery for refractory uveitis under adalimumab (ADA) therapy.

Study design

Single-center cohort study between 2016 and 2019.

Methods

In uveitis patients undergoing intraocular surgery under ADA treatment, we collected clinical data before surgery, and at the first visit, 6 months and last visit after surgery (follow-up 19.3 ± 8.1 months). Primary outcomes were visual acuity (VA) improvement in patients after cataract surgery, intraocular pressure (IOP) in patients after trabeculectomy and intraocular inflammation in all patients. Secondary outcomes were activated inflammation, vitreous opacity (OCV), uveitic macula edema (UME) and infection.

Results

Of 81 patients (161 eyes) initiated ADA therapy for uveitis, 19 patients (23 eyes) underwent intraocular surgery and were analyzed. Twelve of 18 eyes (66.6%) that underwent cataract surgery or vitrectomy with/without cataract surgery had improved VA at the last visit compared to before surgery. All 5 eyes that underwent trabeculectomy showed controlled IOP 6 months after surgery. Intraocular inflammation was resolved in 22 of 23 eyes at the first postoperative visit. Postoperative intraocular inflammation recurred in 3 eyes; 2 with UME, 1 with OCV. No eyes developed infection postoperatively. Preoperative ADA therapy duration was unrelated to relapse of intraocular inflammation.

Conclusion

Surgery for refractory uveitis under ADA treatment is safe and achieves good visual outcome and uveitis control if inflammation exists before surgery. ADA does not increase the risk of infections. Intraoperative findings of UME at surgery requires attention for postoperative relapse.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Nussenblatt RB. Elements of the immune system and concepts of intraocular inflammatory disease pathogenesis. In: Nussenblatt RB, Whitcup SM, editors. Uveitis: fundamentals and clinical practice. 4th ed. China: Mosby Elsevier; 2010. p. 1–36.

    Google Scholar 

  2. 2.

    Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51:41–5.

    Article  Google Scholar 

  3. 3.

    Smith RE, Godfrey WA, Kimura SJ. Complications of chronic cyclitis. Am J Ophthalmol. 1976;82:277–82.

    CAS  Article  Google Scholar 

  4. 4.

    Okhravi N, Lightman SL, Towler HMA. Assessment of visual outcome after cataract surgery in patients with uveitis. Ophthalmology. 1999;106:710–22.

    CAS  Article  Google Scholar 

  5. 5.

    Merayo-Lloves J, Power WJ, Rodriguez A, Pedroza-Seres M, Foster CS. Secondary glaucoma in patients with uveitis. Ophthalmologica. 1999;213:300–4.

    CAS  Article  Google Scholar 

  6. 6.

    Mehta S, Linton MM, Kempen JH. Outcomes of cataract surgery in patients with uveitis: a systematic review and meta-analysis. Am J Ophthalmol. 2014;158:676-692.e7.

    Article  Google Scholar 

  7. 7.

    Shimizu A, Maruyama K, Yokoyama Y, Tsuda S, Ryu M, Nakazawa T. Characteristics of uveitic glaucoma and evaluation of its surgical treatment. Clin Ophthalmol. 2014;26:2383–9.

    Article  Google Scholar 

  8. 8.

    Bansal R, Gupta A, Gupta V, Mulkutkar S, Dogra M, Katoch D, et al. Safety and outcome of microincision vitreous surgery in uveitis. Ocul Immunol Inflamm. 2017;25:775–84.

    Article  Google Scholar 

  9. 9.

    Maruyama K, Hashida N, Koh S, Nakazawa T, Nishida K. Efficacy of vitreous surgery for prolonged cases of intraocular inflammatory disease. Nippon Ganka Gakkai Zasshi. 2018;122:393–9 (in Japanese).

    CAS  Google Scholar 

  10. 10.

    Suzuki S. Cataract surgery during anti-TNF-α therapy (infliximab) for Behçet’s disease. J Clinic Exp Ophthalmol. 2013;04:328–33.

    Article  Google Scholar 

  11. 11.

    Fan F, Jia Z, Li K, Zhao X, Ma Q. Cataract surgery combined with micro-incision vitrectomy in patients with Behcet’s disease uveitis. BMC Ophthalmol. 2018;18:158.

    Article  Google Scholar 

  12. 12.

    Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factorα blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352–6.

    Article  Google Scholar 

  13. 13.

    Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125:1075–87.

    Article  Google Scholar 

  14. 14.

    Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–8.

    CAS  Article  Google Scholar 

  15. 15.

    Sakai T, Kanetaka A, Noro T, Tsuneoka H. Intraocular surgery in patients receiving infliximab therapy for Behçet disease. Jpn J Ophthalmol. 2010;54:360–1.

    Article  Google Scholar 

  16. 16.

    Noda E, Yamanishi S, Shiraishi A, Ohashi Y. Cataract surgery under infliximab therapy in a patient with Behçet’s disease. J Ocul Pharmacol Ther. 2009;25:467–70.

    CAS  Article  Google Scholar 

  17. 17.

    Khalil HEDM, el Gendy HA, Raafat HA, Haroun HE, Gheita TA, Bakir HM. The effectiveness of pre- and postoperative infliximab in controlling Behçet’s disease posterior uveitis in patients undergoing vitrectomy: a preliminary study. J Ophthalmol. 2017:8168369. https://pubmed.ncbi.nlm.nih.gov/28484648.

  18. 18.

    Goto H, Zako M, Namba K, Hashida N, Kaburaki T, Miyazaki M, et al. Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflamm. 2019;27:40–50.

    CAS  Article  Google Scholar 

  19. 19.

    Erckens RJ, Mostard RLM, Wijnen PAHM, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250:713–20.

    CAS  Article  Google Scholar 

  20. 20.

    Iannetti L, Accorinti M, Liverani M, Caggiano C, Abdulaziz R, Pivetti-Pezzi P. Optical coherence tomography for classification and clinical evaluation of macular edema in patients with uveitis. Ocul Immunol Inflamm. 2008;16:155–60.

    Article  Google Scholar 

  21. 21.

    Fabiani C, Vitale A, Rigante D, Emmi G, Bitossi A, Lopalco G, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38:407–15.

    Article  Google Scholar 

  22. 22.

    Jabs DA, Nussenblatt RB, Rosenbaum JT, Atmaca LS, Becker MD, Brezin AP, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–16.

    Article  Google Scholar 

  23. 23.

    Nussenblatt RB, Palestine AG, Chan C-C, Roberge F. Standardizatlon of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–71.

    CAS  Article  Google Scholar 

  24. 24.

    Ministry of Health Labour and Welfare Designated Disease Study Group. Diagnostic criteria of Behcet’s disease (revised edition, 2003). In: Health science study: research on Behcet’s disease, final report for 2002. Tokyo: Ministry of Health, Labour and Welfare. 2003. p. 11–13.

  25. 25.

    Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–52.

    CAS  Article  Google Scholar 

  26. 26.

    Ministry of Health Labour and Welfare Designated Disease Study Group. Diagnostic criteria of sarcoidosis. J Jpn Sarcoidosis Soc. 1991;201:159–62 (in Japanese).

  27. 27.

    Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103:1418–22.

    Article  Google Scholar 

  28. 28.

    Ohguro N, Sonoda K-H, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432–5.

    Article  Google Scholar 

  29. 29.

    Nussenblatt RB. Sympathetic ophthalmia. In: Nussenblatt RB, Whitcup SM, editors. Uveitis: fundamentals and clinical practice. 4th ed. China: Mosby Elsevier; 2010. p. 289–302.

    Chapter  Google Scholar 

  30. 30.

    Gupta V, Gupta A, Dogra MR. Posterior sympathetic ophthalmia: a single centre long-term study of 40 patients from North India. Eye (Lond). 2008;22:1459–64.

    CAS  Article  Google Scholar 

  31. 31.

    Yamane S, Sato S, Maruyama-Inoue M, Kadonosono K. Flanged intrascleral intraocular lens fixation with double-needle technique. Ophthalmology. 2017;124:1136–42.

    Article  Google Scholar 

  32. 32.

    Cairns JE. Trabeculectomy: preliminary report of a new method. Am J Ophthalmol. 1968;66:673–9.

    CAS  Article  Google Scholar 

  33. 33.

    Ciftci OU, Ozdemir O. Cataract extraction in Behçet’s disease. Acta Ophthalmol Scand. 1996;74:74–6.

    CAS  Article  Google Scholar 

  34. 34.

    Akova YA, Foster CS. Cataract surgery in patients with sarcoidosis-associated uveitis. Ophthalmology. 1994;101:473–9.

    CAS  Article  Google Scholar 

  35. 35.

    Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum. 2003;48:3013–22.

    CAS  Article  Google Scholar 

  36. 36.

    Wendling D, Balblanc J-C, Brousse A, Lohse A, Lehuede G, Garbuio P, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis. 2005;64:1378–9.

    CAS  Article  Google Scholar 

  37. 37.

    Alfawaz A, Alrashidi S, Kalantan H, Al-Mezaine H, Abu AM. Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet disease. Ann Saudi Med. 2014;34:328–33.

    Article  Google Scholar 

  38. 38.

    Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology. 2014;121:588–95.

    Article  Google Scholar 

  39. 39.

    St. Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451–9.

    CAS  Article  Google Scholar 

  40. 40.

    Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, et al. Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79:286–97.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported by a Grand-in-Aid for Scientific Research (C) 16K11330 and 19K09959 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yoshihiko Usui.

Ethics declarations

Conflicts of interest

K. Kunimi, Financial Support (AbbVie, Eisai, Santen); Y. Usui, Financial Support (AbbVie, Eisai, Santen); K. Tsubota, None; T. Kezuka, None; H. Goto, Advisory board (AbbVie).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding author: Yoshihiko Usui

Supplementary Information

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kunimi, K., Usui, Y., Tsubota, K. et al. Intraocular surgery under adalimumab therapy in patients with refractory uveitis: a single center study of 23 eyes. Jpn J Ophthalmol (2021). https://doi.org/10.1007/s10384-021-00871-3

Download citation

Keywords

  • Anti-TNF-α therapy
  • Adalimumab
  • Uveitis
  • Intraocular surgery